Development of acute myocardial infarction in a young female patient with essential thrombocythemia treated with anagrelide: a case report.
10.5045/kjh.2010.45.2.136
- Author:
Young Hyo LIM
1
;
Young Yiul LEE
;
Jae Hoon KIM
;
Jinho SHIN
;
Jae Ung LEE
;
Kyung Soo KIM
;
Soon Kil KIM
;
Jeong Hyun KIM
;
Heon Kil LIM
Author Information
1. Division of Cardiology, Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Anagrelide;
Essential thrombocythemia;
Acute myocardial infarction
- MeSH:
Adult;
Blood Platelets;
Cyclic Nucleotide Phosphodiesterases, Type 3;
Cytotoxins;
Female;
Humans;
Myeloproliferative Disorders;
Myocardial Infarction;
Quinazolines;
Risk Factors;
Thrombocythemia, Essential;
Thromboembolism
- From:Korean Journal of Hematology
2010;45(2):136-138
- CountryRepublic of Korea
- Language:English
-
Abstract:
Essential thrombocythemia (ET) is a chronic myeloproliferative disorder with a prolonged clinical course. Since this disorder is considered to be at increased risk of thromboembolism, therapy is mainly focused on the decreased risk of thrombohemorrhagic events by use of cytotoxic agents. Anagrelide is a phosphodiesterase III inhibitor which is utilized in the treatment of ET for the reduction of platelets. However, patients treated with anagrelide might experience cardiovascular adverse effects including myocardial infarction (MI), although these events are rare. Herein, we report a case of a 30-year-old female with well controlled ET by anagrelide, who eventually developed an acute non-ST elevation myocardial infarction (MI). There has no found any cardiovascular risk factors in this ET patient, strongly suggesting that anagrelide might be the cause of MI. Therefore, cardiovascular function should be monitored in those patients prescribed with anagrelide.
